NAD+ Research Overview 2026
Complete NAD+ research overview 2026. Sirtuin biology, PARP activity, CD38 pathway, age-related NAD+ decline, NMN vs NR vs direct NAD+ comparison and human trial data.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for hundreds of enzymatic reactions spanning energy metabolism, DNA repair, and gene expression regulation. Its discovery as a central mediator of aging biology — through its roles as a substrate for sirtuins and PARPs — has generated one of the most active areas of longevity research over the past two decades.
Biochemistry and Cellular Roles
Beyond its redox roles, NAD+ serves as a consumed substrate for three enzyme classes with profound relevance to aging biology:
Sirtuins (SIRT1-7) — NAD-dependent protein deacylases that regulate transcription, DNA repair, mitochondrial biogenesis, and metabolic adaptation. Sirtuin activity is directly proportional to NAD+ availability — meaning cellular NAD+ decline with aging translates directly to reduced sirtuin activity and downstream epigenetic dysregulation.
PARPs (Poly-ADP ribose polymerases) — DNA repair enzymes that consume NAD+ as a substrate for ADP-ribosylation. DNA damage activates PARPs, consuming large quantities of NAD+ and potentially depleting cellular reserves — a proposed mechanism linking age-associated DNA damage accumulation to NAD+ decline.
CD38 — A NAD+ consuming enzyme whose expression increases with age and during inflammation. CD38-mediated NAD+ consumption has been characterized as a primary driver of age-associated NAD+ decline, with CD38-knockout animal models showing dramatically elevated NAD+ levels and improved metabolic function in aging.
Age-Associated NAD+ Decline
Human tissue NAD+ levels decline approximately 50% between ages 40 and 60, with the most dramatic declines in metabolically active tissues including skeletal muscle, liver, and brain. This decline has been mechanistically linked to increased PARP activity from cumulative DNA damage, increased CD38 expression during inflammaging, and reduced activity of NAD+ biosynthetic enzymes including NAMPT.
Precursor Research — NMN and NR
NMN (Nicotinamide Mononucleotide) — Enters cells via the Slc12a8 transporter and is converted to NAD+ by NMNAT enzymes. Human trials documented dose-dependent increases in blood NAD+ levels and improvements in muscle insulin sensitivity in older adults.
NR (Nicotinamide Riboside) — Phosphorylated to NMN intracellularly before conversion to NAD+. Multiple human trials documented NAD+ elevation in blood with emerging data on functional outcomes in older adults.
Direct NAD+ — Intravenous and subcutaneous administration bypasses oral bioavailability limitations. Research using direct administration documented more rapid and complete NAD+ elevation than precursor approaches, making it the subject of clinical research in contexts requiring immediate NAD+ restoration.
Published Human Research Highlights
Clinical research has documented improvements in muscle insulin sensitivity in postmenopausal women, reduced arterial stiffness in middle-aged and older adults, and improvements in gait speed and grip strength in older men. Brain NAD+ levels have been measured using phosphorus MRS in human studies, with supplementation-associated increases documented in multiple cohorts.
Research Delivery Considerations
Research protocols have examined multiple delivery routes for NAD+ and its precursors. Intravenous administration produces the most rapid plasma elevation but requires clinical infrastructure. Subcutaneous administration of NAD+ has been studied as a practical alternative for research protocols requiring direct NAD+ delivery rather than precursor conversion. Oral NMN and NR remain the most widely studied routes in human clinical trials due to practical administration considerations.
NAD+ is a research compound. Information presented is for laboratory and research reference only. For research use only per Ares Research terms.
Related Research Articles
Sleep and Recovery Peptide Research 2026
Sleep architecture and circadian biology connect to several distinct research peptide categories — pineal gland-derived compounds, GH-axis secretagogues timed to nocturnal pulses, and DSIP's contested but historically significant sleep research thread. Here's how they relate.
NAD+ vs Glutathione Research Comparison 2026
NAD+ and Glutathione are both studied in cellular longevity and antioxidant research contexts — but their mechanisms are distinct enough that comparing them as alternatives misses the point. Here's what each one does and why they're often studied together.
MOTS-c Clinical Studies and Findings
MOTS-c Clinical Studies and Findings: research-context overview for laboratory reference at Ares Research.
Epithalon Clinical Studies and Findings
Epithalon Clinical Studies and Findings: research-context overview for laboratory reference at Ares Research.
Glutathione Clinical Studies and Findings
Glutathione Clinical Studies and Findings: research-context overview for laboratory reference at Ares Research.
NAD+ Clinical Studies and Findings
NAD+ Clinical Studies and Findings: research-context overview for laboratory reference at Ares Research.
Neutral, moderated research discussion. Laboratory use only.
More compound guides, hubs, and educational research materials.